Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 11/2008

01-11-2008 | Gastrointestinal Oncology

Detection of Survivin-Expressing Circulating Cancer Cells (CCCs) in Peripheral Blood of Patients with Gastric and Colorectal Cancer Reveals High Risks of Relapse

Authors: Shang-mian Yie, PhD, Be Lou, BS, Shang-rong Ye, MD, Mei Cao, PhD, Xu He, PhD, Ping Li, MD, Kang Hu, MS, Lin Rao, BS, Sheng-min Wu, BS, Hai-bo Xiao, MS, En Gao, BS

Published in: Annals of Surgical Oncology | Issue 11/2008

Login to get access

Abstract

Background

We previously demonstrated that the detection of circulating cancer cells (CCCs) expressing survivin mRNA could provide valuable information for predicting metastasis and recurrence in breast cancer. The objective of this study was to investigate whether or not the detection of survivin expression in the peripheral blood could also have significant effects on the clinical outcomes of patients with gastric and colorectal cancer.

Methods

Survivin-expressing CCCs in peripheral blood samples obtained from 55 gastric cancer patients, 86 colorectal cancer patients, and 87 healthy volunteers were quantitatively examined by using a RT-PCR ELISA. Its clinical significance was statistically evaluated.

Results

The CCCs in the peripheral blood samples were detected in 45.4% and 44.0% of gastric and colorectal cancer patients, respectively. The presence of survivin-expressing CCCs was found to be significantly associated with the degree of tumor penetration, nodal status, and disease stages for both types of cancers. During a follow-up period of 36 months, patients who had a positive detection at the time of the initial assay test had a higher relapse rate than those who had a negative detection. As well, survivin-expressing CCCs were statistically shown to be a significant and independent predictor for cancer recurrence. The detection of survivin-expressing CCCs was also demonstrated to be more accurate in terms of predicting recurrence than traditional detection methods such as plasma carcinoembryonic antigen (CEA) measurements.

Conclusion

The detection of CCCs expressing survivin mRNA could be used to accurately identify gastric and colorectal cancer patients with high risks of relapse.
Literature
1.
Greene FL, Balch CM, Fleming ID, et al. AJCC Manual for Staging of Cancer, 6th edition. New York: Springer Verlag, 2002
2.
Bruneton JN, Francois E, Padovani B, et al. Primary tumor staging of gastric and colorectal cancer. Eur Radiol 1996; 6:140–6.PubMed
3.
Goldberg RM, Fleming TR, Tangen CM, et al. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Ann Intern Med 1998; 129:27–35.PubMed
4.
Marrelli D, De Stefano A, de Manzoni G, et al. Prediction of recurrence after radical surgery for gastric cancer: a scoring system obtained from a prospective multicenter study. Ann Surg 2005; 241:247–55.PubMedCrossRef
5.
Wolfrum F, Vogel I, Fändrich F, et al. Detection and clinical implications of minimal residual disease in gastro-intestinal cancer. Langenbecks Arch Surg 2005; 390:430–41.PubMedCrossRef
6.
Feezor RJ, Copeland EM 3rd, Hochwald SN. Significance of micrometastases in colorectal cancer. Ann Surg Oncol 2002; 9:944–53.PubMedCrossRef
7.
Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82:2605–10.PubMed
8.
Vogel I, Kalthoff H. Disseminated tumour cells. Their detection and significance for prognosis of gastrointestinal and pancreatic carcinomas. Virchows Arch 2001; 439:109–17.PubMedCrossRef
9.
Zieglschmid V, Hollmann C, Böcher O. Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci 2005; 42:155–96.PubMedCrossRef
10.
Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58:5071–4.PubMed
11.
Sarela AI, Macadam RC, Farmery SM, et al. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000; 46:645–50.PubMedCrossRef
12.
Miller M, Smith D, Windsor A, et al. Survivin gene expression and prognosis in recurrent colorectal cancer. Gut 2000; 48:137–8.CrossRef
13.
Wang TT, Qian XP, Liu BR. Survivin: potential role in diagnosis, prognosis and targeted therapy of gastric cancer. World J Gastroenterol 2007; 13:2784–90.PubMed
14.
Ambrosini G, Adida C, Altieri D. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997:917–21.
15.
Yie SM, Luo B, Ye NY, et al. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA. Clin Exp Metastasis 2006; 23:279–89.PubMedCrossRef
16.
Fenogilo-Preiser C, Carneiro F, Correa P, et al. (2000) Gastric carcinoma. In: Hamilton S, Aaltonin L, (eds). Pathology and Genetics. Tumors of the Digestive System, volume 1. Lyon Press: Lyon, France, pp 37–52
17.
Herman P, Sobbing LH. UICC/TNM Classification of Malignant Tumors, 4th edition. New York: Springer-Verlag, 1987:47–9
18.
Posner MR, Mayer RJ. The use of serologic tumor markers in gastrointestinal malignancies. Hematol Oncol Clin North Am 1994; 8:533–53.PubMed
19.
Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005; 23:338–51.PubMed
20.
Wang ZN, Xu HM, Jiang L, et al. Expression of survivin in primary and metastatic gastric cancer cells obtained by laser capture microdissection. World J Gastroenterol 2004; 10:3094–8.PubMed
21.
Tsuburaya A, Noguchi Y, Yoshikawa T, et al. An anti-apoptosis gene, survivin and telomerase expression in gastric cancer. Hepatogastroenterology 2002; 49:1150–2.PubMed
22.
Chen WC, Liu Q, Fu JX, et al. Expression of survivin and its significance in colorectal cancer. World J Gastroenterol 2004; 10:2886–9.PubMed
23.
Sarela AI, Macadam RC, Farmery SM, et al. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000; 46:645–50.PubMedCrossRef
24.
Ebert W, Muley T, Drings P. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Anticancer Res 1996; 16:2161–8.PubMed
25.
Torosian MH, Daly JM. An evaluation of the clinical usefulness of CEA in colorectal cancer. Oncology (Williston Park) 1991; 5:41–4.
26.
Sakamoto J, Nakazato H, Teramukai S, et al. Association between preoperative plasma CEA levels and the prognosis of gastric cancer following curative resection. Tumor Marker Committee, Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan. Surg Oncol 1996; 5:133–9.PubMed
27.
Ballesta AM, Molina R, Filella X, et al. Carcinoembryonic antigen in staging and follow-up of patients with solid tumors. Tumour Biol 1995; 16:32–41.PubMedCrossRef
28.
Mehes G, Witt A, Kubista E, et al. Circulating breast cancer cells are frequently apoptotic. Am J Pathol 2001; 159:17–20.PubMed
29.
Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cells collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82:2605–10.PubMed
30.
Pizzoferrato E, Liu Y, Gambotto A, et al. Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. Cancer Res 2004; 64:8381–8.PubMedCrossRef
Metadata
Title
Detection of Survivin-Expressing Circulating Cancer Cells (CCCs) in Peripheral Blood of Patients with Gastric and Colorectal Cancer Reveals High Risks of Relapse
Authors
Shang-mian Yie, PhD
Be Lou, BS
Shang-rong Ye, MD
Mei Cao, PhD
Xu He, PhD
Ping Li, MD
Kang Hu, MS
Lin Rao, BS
Sheng-min Wu, BS
Hai-bo Xiao, MS
En Gao, BS
Publication date
01-11-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 11/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0069-x

Other articles of this Issue 11/2008

Annals of Surgical Oncology 11/2008 Go to the issue

Hepatic and Pancreatic Tumors

Annexin II Overexpression Predicts Rapid Recurrence after Surgery in Pancreatic Cancer Patients Undergoing Gemcitabine-Adjuvant Chemotherapy

Gastrointestinal Oncology

Prediction of Lymph Node Status in Superficial Esophageal Carcinoma

Gastrointestinal Oncology

Oncological Outcome After Local Excision of Rectal Carcinomas

Breast Oncology

Intraoperative Radioisotope Injection for Sentinel Lymph Node Biopsy

Laboratory Research

Metastatic Dormancy Imposed by the Primary Tumor: Does it Exist in Humans?

Melanomas

Skin Mapping With Punch Biopsies for Defining Margins in Melanoma: When You Don’t Know How Far to Go